Notice of Intent to Publish a Funding Opportunity Announcement for Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

NOTE: This is a Forecasted Opportunity.

The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications to expand the research scope and leverage the gains made through the Investigation of the Transmission of KSHV initiatives (RFA-CA-18-013 and RFA-CA-20-046) to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-associated syndromes such multicentric Castleman disease (MCD), primary effusion lymphoma (PEL) and KSHV inflammatory cytokine syndrome (KICS) or ameliorate the severity of disease. A therapeutic KSHV vaccine could be helpful in preventing or treating KSHV disease in people who are already infected with KSHV.

This Notice is being provided to allow potential applicants time to develop responsive projects and meaningful collaborations.


Estimated Post Date: Oct 02, 2023
Estimated Application Due Date: Dec 14, 2023 




Medical - Basic Science
Medical - Translational

External Deadline

December 14, 2023